$31.59
1.65% yesterday
Nasdaq, Jul 18, 10:00 pm CET
ISIN
CA98420N1050
Symbol
XENE
Sector
Industry

Xenon Pharmaceuticals Inc. Stock price

$31.59
-0.31 0.97% 1M
-6.93 17.99% 6M
-7.61 19.41% YTD
-10.08 24.19% 1Y
+0.42 1.35% 3Y
+18.78 146.60% 5Y
+20.19 177.11% 10Y
+21.09 200.86% 20Y
Nasdaq, Closing price Fri, Jul 18 2025
-0.53 1.65%
ISIN
CA98420N1050
Symbol
XENE
Sector
Industry

Key metrics

Basic
Market capitalization
$2.5b
Enterprise Value
$1.9b
Net debt
positive
Cash
$549.6m
Shares outstanding
76.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
328.6 | 345.2
EV/Sales
255.3 | 268.2
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
94.6%
Return on Equity
-31.0%
ROCE
-41.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.5m | $7.1m
EBITDA
$-290.4m | $-339.8m
EBIT
$-293.0m | $-349.2m
Net Income
$-251.5m | $-313.8m
Free Cash Flow
$-202.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-31.8% | -22.8%
EBIT
-30.8% | -25.0%
Net Income
-33.3% | -33.9%
Free Cash Flow
-28.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,871.7% | -4,758.5%
EBIT
-3,906.6%
Net
-3,352.6% | -4,395.6%
Free Cash Flow
-2,703.9%
More
EPS
$-3.2
FCF per Share
$-2.6
Short interest
5.4%
Employees
322
Rev per Employee
$0.0
Show more

Is Xenon Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Xenon Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

24x Buy
96%
1x Hold
4%

Analyst Opinions

25 Analysts have issued a Xenon Pharmaceuticals Inc. forecast:

Buy
96%
Hold
4%

Financial data from Xenon Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.50 7.50
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 73 73
41% 41%
975%
- Research and Development Expense 227 227
32% 32%
3,031%
-290 -290
32% 32%
-3,872%
- Depreciation and Amortization 2.62 2.62
31% 31%
35%
EBIT (Operating Income) EBIT -293 -293
31% 31%
-3,907%
Net Profit -251 -251
33% 33%
-3,353%

In millions USD.

Don't miss a Thing! We will send you all news about Xenon Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenon Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
21 days ago
VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of ...
Neutral
GlobeNewsWire
22 days ago
VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,750 share options. All...
Neutral
GlobeNewsWire
25 days ago
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications
More Xenon Pharmaceuticals Inc. News

Company Profile

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Head office Canada
CEO Ian Mortimer
Employees 322
Founded 1996
Website www.xenon-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today